Vital KSK Holdings, Inc. · TSE:3151
Vital KSK — 9M FY2023 Earnings Presentation
13 slides from Vital KSK's earnings presentation, February 2023
Slide 1: Financial Results for the First Nine Months of the Fiscal Year Ending March 31, 2023
Towards realization of healthy and prosperous society Financial Results for the First Nine Months of the Fiscal Year Ending March 31, 2023 (the 14th term) February 2023 I am Taisuke Murai, President & CEO of VITAL KSK HOLDINGS, INC. I would like to present to you a summary of the financial results f
Slide 2: Financial Highlights for the First Nine Months
1 Financial Highlights for the First Nine Months of the Fiscal Year Ending March 31, 2023 2 First of all, I will provide an explanation with respect to financial highlights for the first nine months of the fiscal year ending March 31, 2023. 2
Slide 3: Summary of Income for the First Nine Months
▍ Summary of Income for the First Nine Months of the Fiscal Year Ending March 31, 2023 (Million yen, %) Year ending March 31, 2023 Previous year's results FY2022 3Q Results Ratio to net Ratio to net Achievement Amount Amount YoY sales sales rate* Net sales 439,329 ‒ 443,190 ‒ 100.9 78.1 Operating pr
Slide 4: Profit by segment
▍ Profit by segment Prescription drugs 99.5% Reagents and medical devices 120.7% OTC drugs 108.7% (Million yen, %) Veterinary Drug Wholesale Pharmaceutical Wholesale Business*1 Pharmacy Business*2 Other Businesses*4 Business*3 Ratio to net Results YoY Results YoY Results YoY Results YoY sales Net sa
Slide 5: Veterinary Drug Wholesale and Other Businesses results
Next, I will explain the results of the Veterinary Drug Wholesale Business. Net sales amounted to ¥8,157 million, which is 103.9% of the level a year earlier, due to increased sales of high profit products. The segment also posted gross profit of ¥1,264 million yen, which is 102.6% of the level a ye
Slide 6: Full-year Earnings Forecasts for the Fiscal Year Ending March 31, 2023
2 Full-year Earnings Forecasts for the Fiscal Year Ending March 31, 2023 5 I will now move on the earnings forecasts for the fiscal year ending March 31, 2023. 5
Slide 7: Full-year Earnings Forecasts
▍ Full-year Earnings Forecasts for the Fiscal Year Ending March 31, 2023 (Million yen, %) Year ending March 31, 2023 Previous year's results Full-year Earnings Forecasts Amount Ratio to net sales Amount Ratio to net sales YoY Net sales 577,249 ‒ 567,300 ‒ 98.3 Operating profit 2,945 0.51 1,940 0.34
Slide 8: Strengthening of shareholder returns
3 (Reshown) From materials released on October 28, 2022 Strengthening of shareholder returns 7 Finally, I would like to once again explain the "strengthening of shareholder returns" as announced on October 28, 2022. 7
Slide 9: Dividend on equity (DOE) policy and revised dividend forecast
▍ We have adopted dividend on equity (DOE) as an index and our future dividend policy is to maintain a DOE of 2% or more. Change in forecast dividend per share for the current fiscal year (ending March 31, 2023) Before revision After revision An annual dividend of 24 yen An annual dividend of 39 yen
Slide 10: Total shareholder return target of 50% or more
soundness. However, the Company has set the total shareholder return target at 50% or more based on the maximum consideration for shareholders and will make returns to shareholders accordingly. 8
Slide 11: Shareholder Returns Policy for Year Ending March 31, 2023
▍ Shareholder Returns Policy for Year Ending March 31, 2023 ◼ Changes in net profit Year ending March 31, 2023 Year ended March 31, 2021 Year ended March 31, 2022 (forecast) Profit attributable to owners of parent 1,171 million yen 4,770 million yen 4,400 million yen ◼ Changes in basic earnings per
Slide 12: Note on Forward Looking Statements
▍ Note on Forward Looking Statements The Company's current plans, strategies, earnings forecasts and other forward-looking statements in these materials are based on information currently available to the Company, and include potential risks and uncertainties. Please be aware that there is a possibi
Slide 13: Contact for Inquiries
▍ Contact for Inquiries Corporate Communications Department TEL: 03-5787-8550 Mail: [email protected] Contacts: Sato, Nanjo 11 Finally, I would like to ask you to direct any inquiries your might have about today's presentation to our Corporate communications Department. This brings me to the end of